budesonide + montelukast + salbutamol

A combination therapy consisting of budesonide (a corticosteroid), montelukast (a leukotriene receptor antagonist), and salbutamol (a short-acting beta-2 adrenergic agonist). This triple combination targets multiple pathways involved in asthma pathophysiology: budesonide reduces airway inflammation, montelukast blocks leukotriene-mediated inflammation, and salbutamol provides bronchodilation for symptom relief. Clinical evidence suggests this combination approach may be more effective than monotherapy in improving lung function, reducing inflammatory markers, and alleviating symptoms in patients with persistent asthma.